Samsung Bioepis Co., Ltd. ("Samsung Bioepis") announced today that the company has entered into a license, development and ...

Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Harrow, Inc. (NASDAQ:HROW) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 10, William ...

Fintel reports that on July 11, 2025, Cantor Fitzgerald initiated coverage of Harrow (NasdaqGM:HROW) with a Overweight ...

Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Harrow, Inc. (NASDAQ:HROW) is not on our list of 30 Most Popular Stocks Among Hedge Funds.At the end of the fourth quarter, Harrow, Inc. (NASDAQ:HROW) was held by 14 hedge fund portfolios ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a ...

Harrow, Inc. (NASDAQ:HROW) started in 2014 as an ophthalmic pharmacy company with no products and no revenue.The business model, copying pharma giants Alcon and Allergan, was to first enter the ...

HROW's sales reached $49 million, up 40% in the six months ended June. As the newly launched products continue to ramp up, I think we should see accelerated growth in the second half of the year.